IRIS Institutional Research Information System - AIR Archivio Istituzionale della Ricerca

GRAZIOSO, GIOVANNI
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 7.780
NA - Nord America 7.404
AS - Asia 7.336
Continente sconosciuto - Info sul continente non disponibili 1.167
SA - Sud America 663
AF - Africa 191
OC - Oceania 40
Totale 24.581
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 7.069
IT - Italia 2.367
CN - Cina 2.294
SG - Singapore 1.841
GB - Regno Unito 1.681
DE - Germania 810
HK - Hong Kong 688
RU - Federazione Russa 655
BD - Bangladesh 628
SE - Svezia 577
BR - Brasile 473
IN - India 431
VN - Vietnam 384
FR - Francia 357
NL - Olanda 227
TR - Turchia 227
KR - Corea 224
CA - Canada 200
IE - Irlanda 195
JP - Giappone 190
FI - Finlandia 176
UA - Ucraina 163
ID - Indonesia 114
DK - Danimarca 106
CH - Svizzera 88
EU - Europa 79
ES - Italia 75
CI - Costa d'Avorio 67
PL - Polonia 62
MX - Messico 60
CO - Colombia 54
AR - Argentina 53
PK - Pakistan 50
AT - Austria 43
ZA - Sudafrica 41
BE - Belgio 39
IQ - Iraq 33
IR - Iran 32
AU - Australia 31
CL - Cile 29
PH - Filippine 29
EC - Ecuador 24
EG - Egitto 19
TH - Thailandia 19
BY - Bielorussia 18
GR - Grecia 18
TW - Taiwan 17
LV - Lettonia 16
MY - Malesia 16
CZ - Repubblica Ceca 15
PT - Portogallo 14
RO - Romania 14
JM - Giamaica 13
UZ - Uzbekistan 13
SA - Arabia Saudita 12
AE - Emirati Arabi Uniti 11
DZ - Algeria 11
PE - Perù 10
PR - Porto Rico 10
AL - Albania 9
CR - Costa Rica 9
MA - Marocco 9
NG - Nigeria 9
NP - Nepal 9
VE - Venezuela 9
KE - Kenya 8
NO - Norvegia 8
AZ - Azerbaigian 7
JO - Giordania 7
LU - Lussemburgo 7
NZ - Nuova Zelanda 7
GE - Georgia 6
GT - Guatemala 6
IL - Israele 6
RS - Serbia 6
SI - Slovenia 6
HN - Honduras 5
HU - Ungheria 5
OM - Oman 5
PY - Paraguay 5
TT - Trinidad e Tobago 5
BG - Bulgaria 4
BO - Bolivia 4
BZ - Belize 4
CM - Camerun 4
DO - Repubblica Dominicana 4
LB - Libano 4
LK - Sri Lanka 4
LT - Lituania 4
PA - Panama 4
SV - El Salvador 4
TN - Tunisia 4
YE - Yemen 4
BS - Bahamas 3
GA - Gabon 3
KG - Kirghizistan 3
KW - Kuwait 3
MD - Moldavia 3
MM - Myanmar 3
MO - Macao, regione amministrativa speciale della Cina 3
Totale 23.434
Salva come PNG Salva come JPEG
Città #
Southend 1.371
Singapore 1.009
Ashburn 870
Milan 817
Hong Kong 576
Dallas 474
Beijing 436
San Jose 416
Chandler 398
Santa Clara 287
Seattle 284
Council Bluffs 244
Los Angeles 231
Princeton 214
Wilmington 191
Dublin 189
Hefei 183
Fairfield 179
New York 177
Hanover 147
Ann Arbor 143
Ho Chi Minh City 125
Frankfurt am Main 120
Dearborn 118
Munich 118
Bengaluru 117
Woodbridge 113
Nanjing 111
Houston 110
Rome 108
Lauterbourg 106
Buffalo 105
Boardman 104
Guangzhou 101
Hanoi 101
Mountain View 95
Moscow 86
Shanghai 86
Jacksonville 84
Redmond 83
Helsinki 78
Redwood City 75
Jakarta 72
Cambridge 69
Abidjan 67
Tokyo 65
Naples 64
Seoul 64
Somerville 62
Hangzhou 56
Jinan 55
Chicago 54
Des Moines 53
The Dalles 53
Toronto 53
Serra 51
Sakarya 47
Cangzhou 46
Istanbul 46
Andover 44
Bogotá 44
São Paulo 43
Tianjin 43
Columbus 42
Phoenix 42
Changsha 41
Shenyang 39
Turin 38
Berlin 36
Warsaw 36
London 33
Shenzhen 33
Medford 32
Montreal 32
Florence 29
Brussels 28
Chengdu 28
Lugano 27
Amsterdam 26
Nanchang 26
Nuremberg 26
Orem 26
Eitensheim 25
Atlanta 24
San Diego 24
Haiphong 23
Hamburg 23
Fuzhou 22
Mexico City 21
Mumbai 21
Stockholm 21
Zhengzhou 21
Barcelona 20
Brooklyn 20
Lund 20
Rio de Janeiro 20
Dalian 19
Johannesburg 19
Odernheim 19
Washington 19
Totale 13.132
Salva come PNG Salva come JPEG
Nome #
Agonisti nicotinici selettivi nel trattamento di patologie del Sistema Nervoso Centrale 617
The response of Escherichia coli biofilm to salicylic acid 556
Systematic Development of Peptide Inhibitors Targeting the CXCL12/HMGB1 Interaction 530
Structure-based drug design, synthesis and biological assays of P. falciparum Atg3-Atg8 protein-protein interaction inhibitors 485
Computationally Driven Structure Optimization, Synthesis, and Biological Evaluation of Imidazole-Based Proprotein Convertase Subtilisin/Kexin 9 (PCSK9) Inhibitors 458
PCSK9 inhibitors: a patent review 2018-2023 403
Novel tricyclic Delta(2)-isoxazoline and 3-oxo-2-methyl-isoxazolidine derivatives: synthesis and binding affinity at neuronal nicotinic acetylcholine receptor subtypes 392
Rational design of allosteric modulators of the aromatase enzyme: An unprecedented therapeutic strategy to fight breast cancer 366
Modification of the anabaseine pyridine nucleus allows achieving binding and functional selectivity for the α3β4 nicotinic acetylcholine receptor subtype [Modification of the anabaseine pyridine nucleus allows achieving binding and functional selectivity for the alpha 3 beta 4 nicotinic acetylcholine receptor subtype] 341
Exploring Proprotein Convertase Subtilisin/Kexin 9 (PCSK9) Autoproteolysis Process by Molecular Simulations: Hints for Drug Design 336
New analogues of epiboxidine incorporating the 4,5-dihydroisoxazole nucleus: Synthesis, binding affinity at neuronal nicotinic acetylcholine receptors, and molecular modeling investigations 288
Application of the Ugi reaction with multiple amino acid-derived components : synthesis and conformational evaluation of piperazine-based minimalist peptidomimetics 286
Elagolix analogues as potential new GnRH antagonists: design, synthesis and characterization 269
Natural compounds targeting E. Coli WRBA as antibiofilm agents: Virtual screening, design and synthesis of analogs, biological evaluation 265
Synthesis of epibatidine-related Delta(2)-isoxazoline derivatives and evaluation of their binding affinity at neuronal nicotinic acetylcholine receptors 264
Lupin peptides modulate the protein-protein interaction of PCSK9 with the low density lipoprotein receptor in HepG2 cells 263
Orthosteric and allosteric ligands selectively acting at cholinergic receptor subtypes 261
Design, Synthesis, and Pharmacological Characterization of Novel Spirocyclic Quinuclidinyl-Δ2-Isoxazoline Derivatives as Potent and Selective Agonists of α7 Nicotinic Acetylcholine Receptors 257
γ-HYDROXY LACTONE BASED PPARγ NON-AGONISTS AS SAFE AND INNOVATIVE ANTI-DIABETIC AGENTS 252
Molecular dynamics simulations of the Salmonella typhi Vi antigenic polysaccharide and effects of the introduction of a zwitterionic motif 249
Biological Characterization of Computationally Designed Analogs of peptide TVFTSWEEYLDWV (Pep2-8) with Increased PCSK9 Antagonistic Activity 249
Novel ligands for neuronal nicotinic receptor subtypes: synthetic, pharmacological and molecular docking studies 243
Investigation of Chlorella pyrenoidosa Protein as a Source of Novel Angiotensin I-Converting Enzyme (ACE) and Dipeptidyl Peptidase-IV (DPP-IV) Inhibitory Peptides 242
Synthesis, Binding Affinity at Glutamic Acid Receptors, Neuroprotective Effects, and Molecular Modeling Investigation of Novel Dihydroisoxazole Amino Acids 239
Diazabicyclo analogues of maraviroc : synthesis, modeling, NMR studies and antiviral activity 236
Synthesis of enantiomerically pure HIP-A and HIP-B and investigation of their activity as inhibitors of excitatory amino acid transporters 235
Allosteric modulation of alpha7 nicotinic receptors : mechanistic insight through metadynamics and essential dynamics 231
Oxidation State Dependent Conformational Changes of HMGB1 Regulate the Formation of the CXCL12/HMGB1 Heterocomplex 229
The impact of Chirality on Medicinal Chemistry 226
Inhibition of PCSK9D374Y/LDLR Protein–Protein Interaction by Computationally Designed T9 Lupin Peptide 226
Design of novel α7-subtype-preferring nicotinic acetylcholine receptor agonists: application of docking and MM-PBSA computational approaches, synthetic and pharmacological studies 225
Engineering of α-conotoxin MII-derived peptides with increased selectivity for native α6β2* nicotinic acetylcholine receptors 225
Determination of acid dissociation constants of compounds active at neuronal nicotinic acetylcholine receptors by means of electrophoretic and potentiometric techniques 224
Design and synthesis of selective ligands targeting different nAChR subtypes 224
Alpha7 nicotinic acetylcholine receptor agonists: prediction of their binding affinity through a molecular mechanics poisson-boltzmann surface area approach 223
New spirocyclic Δ2-isoxazoline derivatives related to selective agonists of α7 neuronal nicotinic acetylcholine receptors 223
Bifunctional compounds targeting both D2 and non-α7 nACh receptors: design, synthesis and pharmacological characterization 220
Determination of acid dissociation constants of poorly water-soluble nicotinic ligands by means of electrophoretic and potentiometric techniques 219
γ-hidroxy-lactone derivatives as ppar-γ non-agonists blocking cdk5-mediated phosporylation for a safer anti-diabetic treatment 218
Elagolix Sodium Salt and Its Synthetic Intermediates: A Spectroscopic, Crystallographic, and Conformational Study 216
Design of Cyclopentaisoxazoline Amino Acids as Conformationally Constrained Agonists at Glutamate Receptors 215
Trans-Epithelial Transport, Metabolism and Biological Activity Assessment of the Multi-Target Lupin Peptide LILPKHSDAD (P5) and Its Metabolite LPKHSDAD (P5-Met) 215
Towards a safe treatment of Insulin Resistance: γ-hydroxy lactone-based derivatives as PPARγ non-agonists 214
Computational Design, Synthesis, and Biological Evaluation of Diimidazole Analogues Endowed with Dual PCSK9/HMG-CoAR-Inhibiting Activity 214
Isonitrile-Based Multicomponent Synthesis of β-Amino Boronic Acids as β-Lactamase Inhibitors 213
COMPUTATIONAL INVESTIGATION ON SUBSTRATE UPTAKE AND RELEASE IN A GLUTAMATE TRANSPORTER 211
Natural and nature-inspired compounds targeting E. coli WrbA as antibiofilm agents: computational studies, synthesis, and biological evaluation 209
Synthesis of Novel N1-Substituted Bicyclic Pyrazole Amino Acids and Evaluation of Their Interaction with Glutamate Receptors 207
In silico design of agonists targeting the alpha7 nicotinic acetylcholine receptors, their synthesis and preliminary pharmacological evaluation 206
Computational Design and Biological Evaluation of Analogs of Lupin Peptide P5 Endowed with Dual PCSK9/HMG-CoAR Inhibiting Activity 205
Covalent docking of selected boron-based serine beta-lactamase inhibitors 203
Insights on the atropisomeric properties of elagolix and its derivatives 202
Learning to Rank Food Images 202
Nicotine-Modulated Subunit Stoichiometry Affects Stability and Trafficking of α3β4 Nicotinic Receptor 201
Elagolix analogues as potential new GnRH antagonists 196
Lupin LILPKHSDAD (P5) peptide is a novel bi-functional inhibitor of PCSK9, a new target for the hypercholesterolemia treatment 196
Synthesis, chiral resolution, and enantiopharmacology of a potent 2,3-benzodiazepine derivative as noncompetitive AMPA receptor antagonist 195
(-)-HIP-A and (+)-HIP-B: investigation of the pharmacological profile and potential therapeutic applications 195
Unlocking the Antibiofilm Potential of Natural Compounds by Targeting the NADH:quinone Oxidoreductase WrbA 194
Synthesis of Conformationally Constrained Glutamic Acid Homologues and Investigation of Their Pharmacological Profiles 191
Multidisciplinary strategy to investigate new lupin peptide inhibitors of PCSK9 activity as useful approach for cardiovascular disease risk reduction 190
Novel Non-peptide Uracil-derived Human Gonadotropin-Releasing Hormone Receptor Antagonists 188
Enhancing the activity of γ-hydroxy lactone derivatives as innovative peroxisome proliferator-activated receptor γ non-agonists inhibiting cyclin-dependent kinase 5-mediated phosphorylation 183
Disrupting the PCSK9/LDLR protein-protein interaction by an imidazole-based minimalist peptidomimetic 183
Mechanistic Insights into the Antibiofilm Mode of Action of Ellagic Acid 182
Synthesis of novel epibatidine-related derivatives through 1,3-dipolar cycloaddition of pyridinenitrile oxides 182
Synthesis of novel enantiopure 2-isoxazoline and 2-pyrazoline amino acids and their activity at glutamic acid receptors and transporters 180
Analytical, computational and formulation studies on TPGS as P-gp inhibitor 179
Computational approaches in the rational design of improved carbonyl quenchers : focus on histidine containing dipeptides 177
Selective nicotinic agonists to treat pathologies of the central nervous system 175
FYCO1 Peptide Analogs: Design and Characterization of Autophagy Inhibitors as Co-Adjuvants in Taxane Chemotherapy of Prostate Cancer 174
Computational Design, Synthesis, and Biophysical Evaluation of β-Amido Boronic Acids as SARS-CoV-2 Mpro Inhibitors 174
Development of a Three-Dimensional Model for the N-Methyl-D-aspartate NR2A Subunit 174
Novel bicylic delta2-isoxazoline and 3-oxo-isoxazolidine derivatives : synthesis and binding affinity at neuronal nicotinic receptor subtypes 173
Design, synthesis, and pharmacological characterization of novel, potent NMDA receptor antagonists 172
Metadynamic investigations of the aspartate binding at glutamate transporters 169
A potent nonapeptide inhibitor for the CXCL12/HMGB1 heterocomplex: A computational and experimental approach 167
DESIGN, SYNTHESIS AND BIOLOGICAL EVALUATION OF PEPTIDOMIMETIC FALCIPAIN-2 INHIBITORS AS ANTIMALARIAL AGENTS 167
A new class of GnRH receptor modulators endowed with atropisomerism 165
Modulatori Fotosensibili dell’adesione batterica: una nuova strategia per ridurre l’antibiotico-resistenza 164
Synthesis of 3-hydroxy- and 3-carboxy-Delta(2)-isoxazoline amino acids and evaluation of their interaction with GABA receptors and transporters 164
Mechanism of falcipain-2 inhibition by α,β-unsaturated benzo[1,4]diazepin-2-one methyl ester 160
New Hybrid and Mutant PIA and MII Toxins with Greater Affinty and Selectivity for the A6* Subtype 159
Computational Design of Novel Cyclic Peptides Endowed with Autophagy-Inhibiting Activity on Cancer Cell Lines 158
Light-Responsive Modulators of Bacterial Cell Adhesion Proteins: a Novel Strategy against AMR? 156
PCSK9-inhibiting compounds 156
Nature‐Inspired Compounds Targeting Escherichia coli WrbA as Biofilm‐Modulating Agents: Computational Design, Synthesis, and Biological Evaluation 153
Synthesis of new isoxazoline-based acidic amino acids and investigation of their affinity and selectivity profile at ionotropic glutamate receptors 153
Synthesis, chiral resolution and pharmacological evaluation of a 2,3-benzodiazepine-derived noncompetitive AMPA receptor antagonist 152
How computational chemistry and drug delivery techniques can support the development of new anticancer drugs 150
γ-HYDROXY LACTONE BASED PPARγ NON-AGONISTS AS SAFE AND INNOVATIVE ANTI-DIABETIC AGENTS. 146
Synthesis and Molecular Modeling Studies of Derivatives of a Highly Potent Peptidomimetic Vinyl Ester as Falcipain-2 Inhibitors 141
Alkene Epoxidations Mediated by Mn-Salen Macrocyclic Catalysts 141
Investigating the mechanism of substrate uptake and release in the glutamate transporter homologue GltPh through metadynamics simulations 138
Evaluation of binding free Energy of nicotinic agonists by the linear interaction energy (LIE) approach 137
Synthesis and binding affinity at neuronal nicotinic acetylcholine receptors of novel epibatidine-related delta2-isoxazoline derivatives 136
Synthesis and molecular modeling of novel dihydroxycyclopentane-carbonitrile nor-nucleosides by bromonitrile oxide 1,3-dipolar cycloaddition 131
Focused Design of Novel Cyclic Peptides Endowed with GABARAP-Inhibiting Activity 131
Inactivation of TEM-1 by avibactam (NXL-104): Insights from quantum mechanics/molecular mechanics metadynamics simulations 129
Ago-allosteric modulation of nicotinic alpha7 receptors : a mechanistic insight by metadynamics and essential dynamics 128
Totale 22.232
Salva come PNG Salva come JPEG
Categoria #
all - tutte 67.217
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 67.217
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20221.387 0 60 44 67 141 172 203 105 129 113 112 241
2022/20231.793 254 178 167 159 193 262 44 148 180 45 94 69
2023/20241.678 79 97 107 111 310 122 169 86 77 110 203 207
2024/20253.348 146 269 77 310 273 189 178 376 176 261 402 691
2025/20268.761 737 596 957 839 736 493 998 416 792 568 853 776
2026/2027664 553 111 0 0 0 0 0 0 0 0 0 0
Totale 24.581